Your Messages Inbox
Your Article Summary
See Latest ArticlesPositive phase II results for GSK1838262 reported for subjects with post-herpetic neuralgia and a history of inadequate response to gabapentin
GlaxoSmithKline, 10/06/09
GlaxoSmithKline and XenoPort, Inc. announced top–line results from a Phase II clinical trial evaluating GSK1838262/XP13512 in adult patients with neuropathic pain associated with post–herpetic neuralgia who have had a history of inadequate response to gabapentin doses of 1800 mg/day or higher. In this double–blind, two–period cross–over study, 3600 mg/day of GSK 1838262 demonstrated a statistically significant improvement over 1200 mg/day of GSK1838262 on the primary endpoint, which was the change from baseline to the end of the treatment period in the 24–hour average pain intensity score.
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
ARIAD Announces Full Enrollment in Phase 3 Succeed Trial Evaluating Ridaforolimus in Patients with Metastatic Sarcomas
ARIAD Pharmaceuticals, 12/18/09
Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies
Investigational New Drugs, 12/18/09
Prognostic Factors in Idiopathic Pulmonary Fibrosis
The American Journal of the Medical Sciences, 12/17/09
Today in Research & Development...keeping you current
Receive free subspecialty "5-minute updates" via email
GlaxoSmithKline and NanoBio announce OTC licensing agreement for cold sore treatment
GlaxoSmithKline, 12/18/09
ARIAD Announces Full Enrollment in Phase 3 Succeed Trial Evaluating Ridaforolimus in Patients with Metastatic Sarcomas
ARIAD Pharmaceuticals, 12/18/09
CCHIT Appoints Officers
HealthDataManagement, 12/18/09
Article Search
Sponsor